Molecular pathogenesis of Bacillus anthracis infection

Microbes and Infection

Volumn 1, Issue 2, 1999, Pages 131-139

  Little, Stephen F ^a   Ivins, Bruce E ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Anthrax; Bacillus anthracis; Pathogenesis; Vaccine

Indexed keywords

EXOTOXIN; VACCINE;

ANTHRAX; BACILLUS ANTHRACIS; CELL INTERACTION; CHEMICAL STRUCTURE; HUMAN; MACROPHAGE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VACCINATION;

ANTHRAX; ANTHRAX BACILLUS; BACILLUS ANTHRACIS; POSIBACTERIA;

EID: 0032760622     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(99)80004-5     Document Type: Review

References (121)

1. Lincoln R.E., Rhian M.A., Klein F., Fernelius A. Pathogenesis as related to physiological state of anthrax spore and cell. Halvorson H.O. Spores II. 1961;255-272 Burgess Publishing Co., Minneapolis.
2. Lincoln R.E., Walker J.S., Klein F., Haines B.W. Anthrax. Brandly C.A, Jungherr E.L. Advances in veterinary science. 1964;327-368 Academic Press, New York.
3. Quinn C.P., Turnbull P.C.B. Anthrax. Collier L, Balows A, Sussman M. Topley and Wilson's Microbiology and Microbial Infections. 1998;799-818 Arnold, London.
4. Brachman P.S., Friedlander A.M. Anthrax. Plotkin S.A, Mortimer E.A. Vaccines. 1994;729-739 W.B. Saunders Company, Philadelphia.
5. Thorne C.B. Bacillus anthracis. Hoch J.A, Losick R. Biochemistry, physiology, and molecular genetics. 1993;113-124 American Society for Microbiolgy, Washington, D.C.
6. Hanna P. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225:1998;13-35.
7. Friedlander A.M. The anthrax toxins. Saelinger C.B. Trafficking of bacterial toxins. 1990;121-128 CRC Press, Boca Raton, FL.
8. Hedlund K.W. Anthrax toxin: History and recent advances and perspectives. J. Toxicol. 11:1992;41-88.
9. Leppla S.H. The anthrax toxin complex. Alouf J.E, Freer J.H. Sourcebook of bacterial protein toxins. 1991;277-302 Academic Press, Inc. New York.
10. Leppla S.H. Anthrax Toxins. Moss J, Iglewski B, Vaughan M, Tu A.T. Bacterial toxins and virulence factors in disease. 1996;543-572 Marcel Dekker, Inc. New York.
11. Petosa C., Liddington R.C. The anthrax toxin. Parker M.W. Protein toxin structure. 1996;97-121 R.G. Landes Company, Austin, Texas.
12. Hambleton P., Turnbull P.C.B. Anthrax vaccine development: a continuing story. Adv. Biotechnol. Proc. 13:1990;105-122.
13. Turnbull P.C.B. Anthrax vaccines: past, present and future. Vaccine. 9:1991;533-539.
14. Keppie J., Smith H., Harris-Smith P.W. The chemical basis of the virulence of Bacillus anthracis. III. The role of the terminal bacteraemia in death of guinea pigs from anthrax. Br. J. Exp. Pathol. 36:1955;315-322.
15. Smith H., Keppie J., Stanley J.L. The chemical basis of the virulence of Bacillus anthracis. V. The specific toxin produced by B. anthracis in vivo. Br. J. Exp. Pathol. 36:1955;460-472.
16. Harris-Smith P.W., Smith H., Keppie J. Production in vitro of the toxin of Bacillus anthracis previously recognized in vivo. J. Gen. Microbiol. 19:1958;91-103.
17. Stanley J.L., Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26:1961;49-66.
18. Beall F.A., Taylor M.J., Thorne C.B. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J. Bacteriol. 83:1962;1274-1280.
19. Pezard C., Berche P., Mock M. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:1991;3472-3477.
20. Mikesell P., Ivins B.E., Ristroph J.D., Dreier T.M. Evidence for plasmid-mediated toxin production in Bacillus anthracis, Infect. Immun. 39:1983;371-376.
21. Koehler T.M., Dai Z., Kaufman-Yarbray M. Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters. J. Bacteriol. 176:1994;586-595.
22. Sirard J., Mock M., Fouet A. The three Bacillus anthracis toxin genes are coordinately regulated by bicarbonate and temperature. J. Bacteriol. 176:1994;5188-5192.
23. Uchida I., Hornung J.M., Thorne C.B., Klimpel K.R., Leppla S.H. Cloning and characterization of a gene whose product is a trans-activator of anthrax toxin synthesis. J. Bacteriol. 175:1993;5329-5338.
24. Welkos S.L., Lowe J.R., Eden-Mccutchan F., Vodkin M., Leppla S.H., Schmidt J.J. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene. 69:1988;287-300.
25. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature. 385:1997;8833-8838.
26. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:1995;82-87.
27. Klimpel K.R., Molloy S.S., Thomas G., Leppla S.H. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA. 89:1992;10277-10281.
28. Allured V.S., Case L.M., Leppla S.H., McKay D.B. Crystallization of the protective antigen protein of Bacillus anthracis. J. Biol. Chem. 260:1985;5012-5013.
29. Leppla S.H., Friedlander A.M., Cora E.M. Proteolytic activation of anthrax toxin bound to cellular receptors. Fehrenbach F.J, Alouf J.E, Falmagne P, Goebel W, Jeljaszewicz J, Jürgens D, Rappuoli R. Bacterial protein toxins. 1988;111-112 Gustav Fischer, New York.
30. Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:1994;20607-20612.
31. Little S.F., Novak J.M., Lowe J.R., Leppla S.H., Singh Y., Klimpel K.R., Lidgerding B.C., Friedlander A.M. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology. 142:1996;707-715.
32. Benson E.L., Huynh P.D., Finkelstein A., Collier R.J. Identification of residues lining the anthrax protective antigen channel. Biochemistry. 37:1998;3941-3948.
33. Novak J.M., Stein M.P., Little S.F., Leppla S.H., Friedlander A.M. Functional characterization of protease-treated Bacillus anthracis protective antigen. J. Biol. Chem. 267:1992;17186-17193.
34. Singh Y., Klimpel K.R., Arora N., Sharma M., Leppla S.H. The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. J. Biol. Chem. 269:1994;29039-29046.
35. Blaustein R.O., Koehler T.M., Collier R.J., Finkelstein A. Anthrax toxin: Channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. USA. 86:1989;2209-2213.
36. Lesieur C., Vécsey-Semjèn B., Abrami L., Fivaz M., Gisou van der Goot F. Membrane insertion: the strategies of toxins (Review). Mol. Membr. Biol. 14:1997;45-64.
37. Perelle S., Gibert M., Boquet P., Popoff M.R. Characterization of Clostridium perfringens iota-toxin genes and expression in Escherichia coli, Infect. Immun. 61:1993;5147-5156.
38. Singh Y., Klimpel K.R., Quinn C.P., Chaudhary V.K., Leppla S.H. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:1991;15493-15497.
39. Little S.F., Lowe J.R. Location of receptor-binding region of protective antigen from Bacillus anthracis, Biochem. Biophys. Res. Commun. 180:1991;531-537.
40. Escuyer V., Duflot E., Sezer O., Danchin A., Mock M. Structural homology between virulence-associated bacterial adenylate cyclases. Gene. 71:1988;293-298.
41. Robertson D.L., Tippetts M.T., Leppla S.H. Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene. 73:1988;363-371.
42. Bragg T.S., Robertson D.L. Nucleotide sequence and analysis of the lethal factor gene (lef) from Bacillus anthracis, Gene. 81:1989;45-54.
43. Labruyère E., Kochi S.K., Mock M. Functional analysis of the N-terminal region of Bacillus anthracis edema toxin. Freer J, Aitken R, Alouf J.E, Boulnois G, Falmagne P, Fehrenbach F, Montecucco C, Piemont Y, Rappuoli R, Wadström T, Witholt B. Bacterial protein toxins. 1993;271-272 Gustav Fischer Verlag, New York.
44. Little S.F., Leppla S.H., Burnett J.W., Friedlander A.M. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun. 199:1994;676-682.
45. Labruyère E., Mock M., Ladant D., Michelson S., Gilles A.M., Laoide B., Barzu O. haracterization of ATP and calmodulin-binding properties of a truncated form of Bacillus anthracis adenylate cyclase. Biochemistry. 29:1990;4922-4928.
46. Robertson D. Relationships between the calmodulin-dependent adenylate cyclases produced by Bacillus anthracis and Bordetella pertussis, Biochem. Biophys. Res. Commun. 157:1988;1027-1032.
47. Munier H., Blanco F.J., Prêcheur B., Diesis E., Nieto J.L., Craescu C.T., Bârzu O. Characterization of a synthetic calmodulin-binding peptide derived from Bacillus anthracis adenylate cyclase. J. Biol. Chem. 268:1993;1695-1701.
48. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA. 79:1982;3162-3166.
49. Hoover D.L., Friedlander A.M., Rogers L.C., Yoon I.K., Warren R.L., Cross A.S. Anthrax edema toxin differentially regulates lipopolysaccharide-induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect. Immun. 62:1994;4432-4439.
50. O'Brien J., Friedlander A., Dreier T., Ezzell J., Leppla S. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47:1985;306-310.
51. Wright G.G., Mandell G.L. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. M. 164:1986;1700-1709.
52. Quinn C.P., Singh Y., Klimpel K.R., Leppla S.H. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J. Biol. Chem. 266:1991;20124-20130.
53. Arora N., Leppla S.H. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268:1993;3334-3341.
54. Hammond S.E., Hanna P.C. Lethal factor active-site mutations affect catalytic activity in vitro. Infect. Immun. 66:1998;2374-2378.
55. Bhatnagar R., Singh Y., Leppla S.H., Friedlander A.M. Calcium is required for the expression of anthrax lethal toxin activity in the macrophage-like cell line J774A.1. Infect. Immun. 57:1989;2107-2114.
56. Klimpel K.R., Arora N., Leppla S.H. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1994;1093-1100.
57. Kochi S.K., Schiavo G., Mock M., Montecucco C. Zinc content of the Bacillus anthracis lethal factor. FEMS Microbiol. Lett. 124:1994;343-348.
58. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46:1982;86-94.
59. Ezzell J.W., Ivins B.E., Leppla S.H. Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin. Infect. Immun. 45:1984;761-767.
60. Friedlander A.M. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:1986;7123-7126.
61. Hanna P.C., Kruskal B.A., Ezekowitz R.A.B., Bloom B.R., Collier R.J. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol. M. 1:1994;7-18.
62. Leppla S.H., Klimpel K.R., Arora N. Anthrax toxin lethal factor is a metallopeptidase. Freer J, Aitken R, Alouf J.E, Boulnois G, Falmagne P, Fehrenbach F, Montecucco C, Piemont Y, Rappuoli R, Wadström T, Witholt B. Bacterial protein toxins. 1994;386-387 Gustav Fischer, New York.
63. Mènard A., Mock M., Montecucco C. Similarities between the lethal factor of Bacillus anthracis and leukotriene A4 hydrolase. Mol. Microbiol. 18:1996;991-992.
64. Ménard A., Papini E., Mock M., Montecucco C. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem. J. 320:1996;687-691.
65. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., Woude G.F.V. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science. 280:1998;734-737.
66. Escuyer V., Collier R.J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:1991;3381-3386.
67. Gordon V.M., Young W.W.J.R., Lechler S.M., Leppla S.H., Hewlett E.L. Adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis: Different processes for interaction with and entry into target cells. J. Biol. Chem. 264:1989;14792-14796.
68. Gordon V.M., Leppla S.H., Hewlett E.L. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1988;1066-1069.
69. Milne J.C., Collier R.J. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:1993;647-653.
70. Cabiaux V., Wolff C., Ruysschaert J. Interaction with a lipid membrane: a key step in bacterial toxins virulence. Int. J. Biol. Macromol. 21:1997;285-298.
71. Zhao J., Milne J.C., Collier R.J. Effect of anthrax toxin's lethal factor on ion channels formed by the protective antigen. J. Biol. Chem. 270:1995;18626-18630.
72. Koehler T.M., Collier R.J. Anthrax toxin protective antigen: low-pH-induced hydrophobicity and channel formation in liposomes. Mol. Microbiol. 5:1991;1501-1506.
73. Kochi S.K., Martin I., Schiavo G., Mock M., Cabiaux V. The effects of pH on the interaction of anthrax toxin lethal and edema factors with phospholipid vesicles. Biochemistry. 33:1994;2604-2609.
74. Wang X., Mock M., Ruysschaert J., Cabiaux V. Secondary structure of anthrax lethal toxin proteins and their interaction with large unilamellar vesicles: A Fourier-tranform infrared spectroscopy approach. Biochemistry. 35:1996;14939-14946.
75. Wang X., Wattiez R., Mock M., Falmagne P., Ruysschaert J., Cabiaux V. Structure and interaction of PA63 and EF (edema toxin) of Bacillus anthracis with lipid membrane. Biochemistry. 36:1997;14906-14913.
76. Friedlander A.M., Bhatnagar R., Leppla S.H., Johnson L., Singh Y. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect. Immun. 61:1993;245-252.
77. Singh Y., Leppla S.H., Bhatnagar R., Friedlander A.M. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J. Biol. Chem. 264:1989;11099-11102.
78. Hanna P.C., Acosta D., Collier R.J. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA. 90:1995;10198-10201.
79. Hanna P.C., Kochi S., Collier R.J. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol. Biol. Cell. 3:1992;1269-1277.
80. Bhatnagar R., Friedlander A.M. Protein synthesis is required for expression of anthrax lethal toxin cytotoxicity. Infect. Immun. 62:1994;2958-2962.
81. Zwartouw H.T., Smith H. Polyglutamic acid from Bacillus anthracis grown in vivo: Structure and aggressin activity. Biochem. J. 63:1956;437-442.
82. Meynell E., Meynell G.G. The roles of serum and carbon dioxide in capsule formation by Bacillus anthracis. J. Gen. Microbiol. 34:1964;153-164.
83. Cromartie W.J., Bloom W.L., Watson D.W. Studies on infection with Bacillus anthracis I. A histopathological study of skin lesions produced by B. anthracis in susceptible and resistant animal species. J. Infect. Dis. 80:1947;1-13.
84. Green B.D., Battisti L., Koehler T.M., Thorne C.B., Ivins B.E. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:1985;291-297.
85. Makino S., Uchida I., Terakado N., Sasakawa C., Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 171:1989;722-730.
86. Uchida I., Sekizaki T., Hashimoto K., Terakado N. Association of the encapsulation of Bacillus anthracis with a 60 megadalton plasmid. J. Gen. Microbiol. 131:1985;363-367.
87. Uchida I., Makino S., Sasakawa C., Yodhikawa M., Sugimoto C., Terakado N. Identification of a novel gene, dep, associated with depolymerization of the capsular polymer in Bacillus anthracis. Mol. Microbiol. 9:1993;487-496.
88. Vietri N.J., Marrero R., Hoover T.A., Welkos S.L. Identification and characterization of a trans-activator involved in the regulation of encapsulation by Bacillus anthracis. Gene. 152:1995;1-9.
89. Guignot J., Mock M., Fouet A. AtxA activates the transcription of genes harbored by both Bacillus anthracis virulence plasmids. FEMS Microbiol. Lett. 147:1997;203-207.
90. Uchida I., Makino S., Sekizaki T., Terakado N. Cross-talk to the genes for Bacillus anthracis capsule synthesis by atxA, the gene encoding the trans-activator of anthrax toxin synthesis. Mol. Microbiol. 23:1997;1229-1240.
91. Welkos S.L., Friedlander A.M. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4:1988;53-69.
92. Welkos S.L. Plasmid-associated virulence factors of non-toxigenic (pXO1-) Bacillus anthracis, Microb. Pathog. 10:1991;183-198.
93. Ezzell J.W., Mikesell P., Ivins B.E., Leppla S.H. The genetic basis of Pasteur's attenuation of Bacillus anthracis cultures. Koprowski H, Plotkin S.A. The world's debt to Pasteur. 1985;107-116 Alan R. Liss, Inc., New York.
94. Ivins B.E., Ezzell J.W.J.R., Jemski J., Hedlund K.W., Ristroph J.D., Leppla S.H. Immunization studies with attenuated strains of Bacillus anthracis, Infect. Immun. 52:1986;454-458.
95. Sterne M. The use of anthrax vaccines prepared from avirulent (uncapsulated) variants of Bacillus anthracis. J. Vet. Sci. Anim. Indust. 13:1939;307-312.
96. Shlyakhov E.N., Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine. 12:1994;727-730.
97. Shlyakhov E., Rubinstein E. Anthraxin skin testing: an alternative method for anthrax vaccine and post-vaccinal immunity assessment. J. Vet. M. 43:1996;483-488.
98. Ivins B.E., Welkos S.L. Recent advances in the development of an improved, human anthrax vaccine. Eur. J. Epidemiol. 4:1988;12-19.
99. Little S.F., Knudson G.B. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:1986;509-512.
100. Pezard C., Weber M., Sirard J., Berche P., Mock M. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1995;1369-1372.
101. Smith H., Gallop R.C. The chemical basis of the virulence of Bacillus anthracis. VI: An extracellular immunising aggressin isolated from exudates of infected guinea pigs. Br. J. Exp. Pathol. 37:1956;144-155.
102. Puziss M., Wright G.G. Studies on immunity in anthrax X. gel-adsorbed protective antigen for immunization of man. J. Bacteriol. 85:1962;230-236.
103. Turnbull P.C., Broster M.G., Carman J.A., Manchee R.J., Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:1986;356-363.
104. Turnbull P.C., Leppla S.H., Broster M.G., Quinn C.P., Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med. Microbiol. Immunol. (Berl.). 177:1988;293-303.
105. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Pub. Health. 52:1962;632-645.
106. Burgasov P.N., Cherkasskij B.L., Knop A.G., Utengov K.U. Epidemiological efficacy of the anthrax STI vaccine. Z. Mikrobiol. Epidemiol. Immunobiol. 9:1976;27-35.
107. Demicheli V., Rivetti D., Deeks J.J., Jefferson T., Pratt M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine. 16:1998;880-884.
108. Lincoln R.E., Fish D.C. Anthrax toxin. Montie T.C, Kadis S, Ajl S.J. Microbial toxins: bacterial protein toxins. 1970;361-414 Academic Press, New York.
109. Little S.F., Ivins B.E., Fellows P.F., Friedlander A.M. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:1997;5171-5175.
110. Little S.F., Leppla S.H., Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1988;1807-1813.
111. Little S.F., Leppla S.H., Friedlander A.M. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1990;1606-1613.
112. Ivins B., Fellows P., Pitt L., Estep J., Farchaus J., Friedlander A., Gibbs P. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 13:1995;1779-1784.
113. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C.B., Baillie L. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine. 16:1998;810-817.
114. Ivins B.E., Welkos S.L., Little S.F., Crumrine M.H., Nelson G.O. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:1992;662-668.
115. Ivins B.E., Pitt M.L.M., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M., Little S.F., Anderson J.R., Gibbs P.H., Friedlander A.M. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 16:1998;1141-1148.
116. Ivins B.E., Welkos S.L., Knudson G.B., Leblanc D.J. Transposon Tn916 mutagenesis in Bacillus anthracis, Infect. Immun. 56:1988;176-181.
117. Pezard C., Duflot E., Mock M. Construction of Bacillus anthracis mutant strains producing a single toxin component. J. Gen. Microbiol. 139:1993;2459-2463.
118. Ivins B.E., Welkos S.L. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun. 54:1986;537-542.
119. Ivins B.E., Welkos S.L., Knudson G.B., Little S.F. Immunization against anthrax with aromatic compound-dependent (Aro-) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:1990;303-308.
120. Coulson N.M., Fulop M., Titball R.W. Bacillus anthracis protective antigen expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine. 12:1994;1395-1401.
121. Iacono-Connors L.C., Schmaljohn C.S., Dalrymple J.M. Expression of the Bacillus anthracis protective antigen gene by baculovirus and vaccinia virus recombinants. Infect. Immun. 58:1990;366-372.